The Company expects to submit the New Drug Application for Xulane Lo in the second half of 2025. A low dose combination hormonal patch was found to be effective for pregnancy prevention based on ...
PITTSBURGH, May 8, 2025 /PRNewswire/ -- Viatris Inc. (VTRS) (Nasdaq: VTRS), a global healthcare company, today announced positive results of its Phase 3 study (NCT05139121) evaluating the ...
And check out April 18/19 New England Spring Craft & Artisan Show - (Milford, NH) on the Portsmouth Patch calendar ...
December 9, 2011 — Voting in favor of the norelgestromin/ethinyl estradiol transdermal contraceptive patch (Ortho Evra, Jannsen), a US Food and Drug Administration (FDA) advisory panel today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results